AbbVie, kampani yopanga kafukufuku wapadziko lonse lapansi ya biopharmaceutical, yalengeza Health Canada yavomereza SKYRIZI® (risankizumab), kuti azichiza odwala akuluakulu omwe ali ndi nyamakazi ya psoriatic. Mu PsA, SKYRIZI ingagwiritsidwe ntchito yokha kapena kuphatikiza ndi mankhwala ochiritsira omwe si a biologic-modifying antirheumatic drug (cDMARD) (mwachitsanzo, methotrexate).
"SKYRIZI kulandira Chidziwitso Chotsatira pochiza matenda a nyamakazi ya psoriatic kumapereka chiyembekezo chowonjezereka kwa odwala. Zotsatira za pulogalamu ya chipatala cha Phase 3 zimasonyeza kusintha kwa zizindikiro ndi zizindikiro zokhudzana ndi matendawa, "anatero Dr. Kim Alexander Papp, MD, PhD, FRCPC, FAAD, Probity Medical Research.
"Ku AbbVie, timayesetsa kusintha chikhalidwe cha chisamaliro cha anthu omwe alibe chitetezo chamthupi, ndipo tili okondwa ndi chivomerezo cha Health Canada cha SKYRIZI pochiza anthu akuluakulu omwe ali ndi nyamakazi ya psoriatic," adatero Tracey Ramsay, Wachiwiri kwa Purezidenti ndi General Manager, AbbVie Canada.
Ichi ndi chisonyezo chachiwiri cha SKYRIZI ku Canada. Mu Epulo 2019, Health Canada idavomereza SKYRIZI kuti azichiza odwala achikulire omwe ali ndi plaque psoriasis yocheperako omwe amalandila chithandizo chamankhwala kapena phototherapy.